Clinical Trial Update: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS) [Phase 2]

View source ↗

Summary

The update notes the completion of a Phase 2 study evaluating AP-101 in amyotrophic lateral sclerosis, assessing safety, tolerability, pharmacodynamic markers, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AP-101

Snippet

Sponsor: AL-S Pharma | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED